Paunescu, EmiliaSoudani, MyleneClavel, Catherine M.Dyson, Paul J.2017-11-082017-11-082017-11-08201710.1016/j.jinorgbio.2017.07.027https://infoscience.epfl.ch/handle/20.500.14299/142035WOS:000411919000021Following the identification of a ruthenium(II)-arene complex with an ethacrynic acid-modified imidazole ligand, which inhibits glutathione transferase (GST) and is cytotoxic to chemo-resistant cancer cells, a series of structurally related ruthenium(II)- and osmium(II)-p-cymene compounds have been prepared. In these complexes the ethacrynic acid is linked to the metals via appropriately modified pyridine ligands. The influence of the metal center and the metal:ethacrynic acid ratio on the cytotoxicity of the compounds was evaluated with the derivatives with one metal center and two ethacrynic acid moieties being the most potent against chemo-resistant A2780cisR cells (human ovarian cancer cells with acquired resistance to cisplatin). Moreover, compared to a complex with an ethacrynic acid-modified imidazole ligand (RAIMID-EA, Figure 2), these complexes display a significant degree of cancer cell specificity.Bioorganometallic chemistryMetal-based drugsAnticancer drugsDrug resistanceEthacrynic acidtext::journal::journal article::research article